BNP Paribas Financial Markets Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

BNP Paribas Financial Markets boosted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 66.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 565,976 shares of the biopharmaceutical company's stock after acquiring an additional 225,222 shares during the quarter. BNP Paribas Financial Markets owned 0.19% of Amicus Therapeutics worth $6,045,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. grew its holdings in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. grew its holdings in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $32,000. Finally, Headlands Technologies LLC acquired a new stake in Amicus Therapeutics in the second quarter valued at approximately $89,000.

Analyst Upgrades and Downgrades

Several brokerages have commented on FOLD. Morgan Stanley dropped their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a "buy" rating and a $18.00 price target on the stock. Cantor Fitzgerald lifted their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.63.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 30,401 shares of company stock worth $339,363 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Trading Up 0.9 %

NASDAQ FOLD traded up $0.09 on Wednesday, reaching $9.88. 567,376 shares of the company were exchanged, compared to its average volume of 2,679,486. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $2.95 billion, a P/E ratio of -28.79 and a beta of 0.60. The business's fifty day moving average price is $10.65 and its 200 day moving average price is $10.61.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.